DexCom price target lowered to $85 from $100 at RBC Capital

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $85 from $100 but keeps an Outperform rating on the shares. The market misunderstood the conservative initial 2026 guide, which likely sent the stock down 11% after results, and based on the firm’s follow-up conversation with DexCom to clarify, the firm believes this stock reaction is overdone, the analyst tells investors in a research note.